NCT03591744 2018-12-19
Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell Leukemia
City of Hope Medical Center
Phase 1 Withdrawn
Clinical Trials
3 trialsNCT00706953 2015-04-06
A Study of Bortezomib and Pegylated Liposomal Doxorubicin in Patients With Relapsed Multiple Myeloma Previously Treated With Bortezomib
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 2 Withdrawn
NCT01492881 2012-05-11
Study of Vorinostat With Doxil and Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma
UNC Lineberger Comprehensive Cancer Center
Phase 2 Withdrawn